19th Annual Bouchet Conference Recognizes Diversity and … – Yale University

The 19th Annual Bouchet Conference on Diversity and Graduate Education, hosted by the Office for Graduate Student Development and Diversity in the Graduate School of Arts and Sciences, will take place on March 31-April 1, 2023. This years theme The Role of the Academy in Preserving a Democracy will delve into the ways in which the academy, and graduate education in particular, prepares future leaders for service tosociety.

Named for Edward Alexander Bouchet, the first African American doctoral recipient in the United States, the Edward Alexander Bouchet Graduate Honor Society recognizes outstanding scholarly achievement and promotes diversity and excellence in doctoral education and the professoriate. The Bouchet Society was inaugurated on Thursday, September 15, 2005, with a simulcast ceremony held at Yale University and Howard University. There will be 122 inductees this year from 19 Bouchet Graduate Honor Society chapterinstitutions.

Yales Graduate School hosts an annual induction ceremony and simultaneous conference featuring panel presentations and poster sessions from members of the honor society on topics ranging from artificial intelligence to Black feminist literature. The conference will feature a keynote address by this years Bouchet Leadership Award Medal recipient David A. Thomas, President of Morehouse College. Yale will induct six new members to its chapter during the ceremony: William D. Shipman II, MD, PhD, dermatology resident and postdoctoral fellow in the Yale Department of Dermatology; Eric Glover, MMUF PhD, assistant professor adjunct at Yale David Geffen School of Drama; Ngozi Akingbesote, PhD candidate in cellular and molecular physiology; Sandy Chang, MD, PhD, professor of laboratory medicine, pathology, and molecular biophysics and biochemistry; Mariam O. Fofana, MD, PhD, postdoctoral associate in the Department of Epidemiology of Microbial Diseases at the Yale School of Public Health and clinical instructor in emergency medicine at the Yale School of Medicine; and Paola Figueroa-Delgado, PhD candidate in the Department of CellBiology.

The conference will also feature an award ceremony honoring this years Bouchet Graduate Honor Society Distinguished Service Award recipient Karen P. DePauw, Vice President and Dean for Graduate Education at VirginiaTech.

Brief bios of this years Yale Bouchet Graduate Honor Society inductees can be foundbelow:

William D. ShipmanDermatology

William D. Shipman III MD, PhD is a Dermatology resident and postdoctoral fellow in the Yale Department of Dermatology. His research and clinical interests focus on skin of color, wound healing, and hidradenitis suppurativa. He is originally from North Carolina and is a proud graduate of Morehouse College in Atlanta, GA, obtaining a Bachelor of Science degree in Biology. From there, he completed an MD-PhD program at the Weill Cornell/Rockefeller/ Sloan-Kettering Tri-Institutional program in NYC, receiving a PhD in Immunology- studying autoimmune skin diseases and specially discovering that immune cells are dysfunctional in lupus skin, working with Dr. Theresa Lu- a Yale Medicine MD/PhD alumna. During graduate school he also worked on projects in skin fibrosis and lymph node fibroblast function in immunity. At Weill Cornell he was involved in creating the Black and Latino Men in Medicine organization, which has since resulted in consultation from other academic centers. He completed a preliminary year in Internal Medicine at Yale-New Haven Hospital and is currently completing his residency in Dermatology with a combined postdoctoral fellowship component. His postdoctoral work will be done with Dr. Henry Hsia- Professor of Plastic Surgery and Founder of Yale Regenerative Wound Healing Center, studying the role of extracellular vesicles in wound healing and hidradenitis suppurativa. In addition to his clinical and research efforts, Dr. Shipman serves as an advocate to promote diversity, equity, and inclusion within his department and within Dermatologynationally.

Eric M. GloverDramaturgy and DramaticCriticism

Eric M. Glover, MMUF PhD, is an assistant professor adjunct at Yale David Geffen School of Drama, where he practices dramaturgy and dramatic criticism. Glover is the author of African-American Perspectives in Musical Theatre (London: Bloomsbury Publishing Plc, 2023), where he reads representative musicals by and about Black peoplefrom Pauline Elizabeth Hopkins to Stewclosely. Glover is also editing Manifestos for BlackTheatre, Then and Now, a special section of TheatreHistory Studies, with Isaiah Matthew Wooden at Swarthmore. A member of the advisory board for the Web site Extended Play: TheaterBeyond the Theater and also a member of the editorial board for the scholarly journal Studies in Musical Theatre. Glover is also serving as a production dramaturg at Yale Repertory Theatre for Christina Anderson's play the ripple, the wave thatcarried me home. Black Theater History in the Making at Yale School of Drama, Black Women Playwrights, Race and the American Musical from Jerome Kern to Jay Kuo, and Topics in Casting comprise courses taught. Glover is also proud to be the first-ever self-identified African-American dramaturgy and dramatic criticism faculty member at the School of Drama in itshistory.

Ngozi AkingbesoteCellular and MolecularPhysiology

Ngozi is a candidate for the Ph.D. in Cellular and Molecular Physiology with a concentration in Cancer Metabolism at Yale University. Her research focuses on uncovering the mechanisms by which exercise improves therapeutic responses to immunotherapy in triple-negative breast cancer preclinical models. Her first author paper revealing, A precision medicine approach to metabolic therapy for breast cancer in mice, is published in Communications Biology. Ngozi was awarded the Yale Presidents Public Service Fellowship in 2021, where she got the opportunity to work with the Sickle Cell Disease Association of America (Michelles House), a Connecticut-based organization that seeks to use prevention strategies to enhance the quality of life and well-being of the community affected by sickle cell disease (SCD). Additionally, Ngozi was awarded one of the Yale Deans Emerging Scholars Research Awards in 2022. Currently, Ngozi serves as the Outreach chair for the Yale BBS Diversity and Inclusion Collective (YBDIC) where she works to leverage resources within Yales network to create STEM education opportunities for minority undergraduate, community school, and post-baccalaureate students. Ngozi also serves as a Public Service Fellow with Yale McDougal Graduate Student Center, where she helps create opportunities for graduate students to interact with the New Haven community through communityservice.

Sandy ChangTelomere Biology and MolecularDiagnostics

Dr. Sandy Chang is a physician-scientist with a research focus on telomere biology and a clinical interest on molecular diagnostics. He has been an important contributor for over two decades in advancing our understanding of how telomeres, repetitive sequences that cap the ends of eukaryotic chromosomes, protect chromosomal ends from being recognized as damaged DNA. The Chang lab has generated many unique mouse models of telomere dysfunction to address innovative questions in both the aging and cancer fields. For example, his lab was the first to generate a mouse model of human Werner Syndrome that recapitulated many of its clinical aging phenotypes. His lab has published their findings in prestigious scientific journals including Nature, Science and Cell. Dr. Chang has been a direct mentor to many PhD students who have gone on to have productive academic research careers. At Yale College, he teaches two First Year Seminars, Topics in Cancer Biology and Perspectives in Biological Research. In both classes, students learn to read and present primary scientific literature and write research proposals that they use to secure summer research funding. As the Associate Dean of STEM Education at Yale College, Dr. Chang is also the director of the Science, Technology and Research (STARS) Programs. STARS supports successful integration of women and underrepresented minorities into Yale STEM classes and laboratories through peer mentorship, professional development workshops and experiential research opportunities. In this capacity, Dr. Chang has increased by over 300% the number of URM and FGLI undergraduates participating in STARSPrograms.

Mariam FofanaEpidemiology of MicrobialDiseases

Mariam O. Fofana is a Postdoctoral Associate in the Department of Epidemiology of Microbial Diseases at the Yale School of Public Health and a Clinical Instructor in Emergency Medicine at the Yale School of Medicine. Her research focuses on the application of quantitative epidemiologic methods such as mathematical modeling to guide the control of infectious disease threats in under-resourced settings and marginalized populations. Her previous work includes estimating the cost-effectiveness of interventions to prevent and treat HIV in South Africa and quantifying the impact of changes in tuberculosis treatment delivery on transmission. Her current work focuses primarily on immune responses, transmission dynamics and socioeconomic impact of SARS-CoV-2 in an urban informal settlement in Brazil. She is determined to make global health more equitable and sustainable through her research as well as education and advocacyefforts.

Paola Figueroa-DelgadoCellBiology

Paola Figueroa-Delgado is a Ph.D. Candidate in the Department of Cell Biology at the Yale School of Medicine. Her research focuses on studying the underlying mechanisms mediating neuronal remodeling in Caenorhabditis elegans. Her thesis work will increase our understanding of fundamental processes that shape the nervous system and will provide insights into how neurodevelopmental disorders may arise. Paola is a recipient of the National Institutes of Health National Research Service Award Predoctoral Fellowship which supports her thesis work and training. In addition, she is the recipient of Yales Annie Le Fellowship for her contributions to science and to the Yale community. Beyond her thesis work, Paola serves as the Director for the Yale Biological and Biomedical Sciences Diversity and Inclusion Collective (YBDIC), an initiative that aims to engage, empower, and advance underrepresented minorities in the biological and biomedical sciences. Through YBDIC, Paola developed and launched programs that provide science education and communication opportunities to community college, undergraduate, and post-baccalaureate students. Among them: mentoring programs (matching over 70 local and national students with current Yale students); a science communication series; and, most notably, a research symposium which hosted 60 local and national students at Yale. In addition, Paola is Student Coordinator for the Yale BioMed Amgen Scholars Program, where she has mentored and supported over 40 undergraduates pursuing a summer research experience at Yale. Her work in service to Yale and her community have awarded her the Yale-Jefferson Award for Public Service and the Vanderbilt Basic Sciences Hispanic and Latin Heritage Graduate LeaderAward.

Read more here:
19th Annual Bouchet Conference Recognizes Diversity and ... - Yale University

50 Celebrity Activists With a History of Protesting Injustice – Good Good Good

Despite calls for actors, athletes, musicians, and other celebrities to eschew activism to focus on entertainment, there is a long-standing precedent for famous people to leverage their platforms to enact change.

From Harry Belafonte and Sidney Poitier establishing themselves as leaders during the civil rights movement to Leonardo DiCaprio and Jane Fonda among many stars pushing for environmental protections and justice, hundreds if not thousands of celebrities in the last century have pushed the needle on a wide variety of causes.

Todays celebrities commonly use their mantles to protest animal cruelty, police brutality, government surveillance, military action, environmental injustice, and civil rights among dozens of other causes.

Our partners at Stacker have compiled a collection of 50 celebrities from the last 75 years with a history of protest. The list includes actors, athletes, and musicians. Several of the contemporary stars made headlines in 2020 for their efforts in support of the Black Lives Matter movement, appearing at numerous protests in the wake of the killings of Breonna Taylor, George Floyd, and many others. Others were instrumental in successful efforts to shut down the Keystone XL pipeline. The Good Good Good team also made some edits and adjustments to the article.

Keep reading to find out what causes some of your favorite celebrities are fighting for.

PS: You might also like: Good Good Goods Guide To Different Types of Activism

Actor Jane Fonda has been known for her activism throughout her decades-spanning career. She was arrested in 1970 for protesting the Vietnam War.

Despite continued action against the conflict, Fonda avoided further arrests until 2019, when she was arrested five times while protesting fossil fuels and calling for environmental action.

Legendary boxing champion Muhammad Ali became an outspoken figure against the Vietnam War, refusing to join the U.S. Army. Declaring himself a conscientious objector, in part due to his religious beliefs, Ali was arrested and stripped of his titles.

Ali became a countercultural figure for civil rights and pacifism, and his conviction for draft evasion was eventually overturned by the Supreme Court.

Avengers star Mark Ruffalo is one of the highest-profile activists against fracking, participating in multiple protests against oil companies.

Ruffalo also produced and starred in a 2019 anti-fracking film called Dark Waters and co-founded The Solutions Project, an organization providing funding for climate justice projects in the U.S. and Puerto Rico.

While fracking has been a central issue for Ruffalo for decades, the actor also protested against former President Donald Trump's policies during his term, and was one of the few celebrities to call for justice for Palestine in 2021.

As a musician, Alicia Keys has added musical flair to her activism. Keys spoke at various demonstrations protesting Trump administration immigration policies, the nomination of Brett Kavanaugh to the Supreme Court, and police brutality, and contributed several protest songs speaking to some of these issues, notably Perfect Way to Die.

As one of the most prolific celebrities in Hollywood, George Clooney has used his star power time and again to bolster his humanitarian efforts.

Clooney had long been vocal about finding a resolution to the War in Darfur, interfacing with world leaders and the United Nations as well as taking part in a number of documentaries spreading awareness about the conflict. In 2012, Clooney was arrested along with his father during a protest at the Sudanese Embassy in Washington D.C.

In 2020, Clooney and his wife Amal donated $500,000 to the Equal Justice Initiative following the murder of George Floyd.

Actor Rosario Dawson is a well-documented activist, primarily demonstrating in support of the Democratic Party. In 2004, Dawson was arrested during the Republican National Convention while protesting against President George W. Bush. She also protested in Washington D.C. in 2016 while attending a rally and spoke out against the role of money in politics.

Dawson founded the non-profit organization Voto Latino, which works to motivate young Hispanic and Latino Americans to register to vote.

Her political activism led her to a fundraiser for Ben Jealous, a 2018 gubernatorial candidate for Maryland, where she met her previous partner, Senator Cory Booker.

Oscar-winning actor Marlon Brando was influential not only for his roles in films like The Godfather and On the Waterfront, but also for his political idealism and activism.

Brando participated in the movement for civil rights in the 1960s and favored a boycott toward South Africa for its apartheid policies.

In support of Indigenous people in the Americas, Brando refused to accept his Best Actor trophy at the 1973 Academy Awards and sent Native American actor Sacheen Littlefeather to speak on his behalf.

Active in a number of social causes, actor Eartha Kitt advocated for and supported underprivileged children in Los Angeles. Kitt also protested against the Vietnam War, and as with many politically active celebrities at the time, she was surveilled by the CIA. Her most public and vocal criticism of the war came during a White House luncheon that President Lyndon Johnson attended.

Former Superman Christopher Reeve had a well-documented history of human rights and environmental activism dating back to at least the mid-70s. He was very involved with Americas Watch, Amnesty International, The Environmental Air Force, Natural Resources Defense Council, and Save the Children.

He flew to Santiago, Chile, in 1987 in support of 77 actors whom the Pinochet regime threatened to execute.

Thrown from a horse and paralyzed in 1995, Christopher Reeve spent the rest of his life and career advocating for stem cell research and the treatment of neurological disorders. He creating the Christopher and Dana Reeve Foundation to fund research and improve the quality of life for patients, testified in support of federal funding for stem cell research before the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies, and successfully helped get the budget for that National Institute of Health doubled over the course of five years.

The power couple of former Beatle John Lennon and musician and artist Yoko Ono primarily focused on promoting peace with their works of art, with Imagine and Give Peace a Chance being some of the more famous songs from the duo.

The Nixon administration attempted to deport Lennon from the United States over the musician's outspoken leftist politics.

Following Lennons murder in 1980, Ono has continued with her peace activism and art through today; she had a massive retrospective exhibit called Peace is Power in 2019 at the Leipzig Museum of Fine Arts in Germany.

Actor Woody Harrelson has made many of his sociopolitical views known to the public, including his support for marijuana legalization and environmental protection.

At a 1996 protest, Harrelson and several other protesters scaled the Golden Gate Bridge to hang up a sign criticizing Maxxam Inc. CEO Charles Hurwitz.

The outspoken activist and vegan narrated the 2020 documentary Kiss the Ground, which centers on promoting regenerative agriculture as a method for mitigating ecologically damaging farming practices from fossil-fuel use to factory farming.

After coming out at the Human Rights Campaigns Time to Thrive conference in 2014, actor Elliot Page became a public advocate for LGBTQ+ rights. In an anti-Donald Trump protest after the presidents inauguration, a video of Page debating a homophobic preacher went viral online.

After coming out as transgender in December of 2020, Page has become an outspoken advocate and activist for trans issues.

Being one of the most famous actors in film today benefited Leonardo DiCaprios environmental activism. For the bulk of his career, DiCaprio has been active in efforts for preservation and combating climate change.

His activism led to him conferring with national leaders, donating millions of dollars to environmental causes, attending marches, and speaking out about climate change in his acceptance speech for Best Actor at the 88th Academy Awards.

He formed the Leonardo DiCaprio Foundation in 1998 (now part of Earth Alliance), which forms partnerships with organizations, experts, and activists to foster biodiversity and mitigate climate change.

In support of the Black Lives Matter movement, musical artist Janelle Monae wrote and performed a protest song called Hell You Talmbout, which invoked the names of several Black Americans who were victims of police violence and racially motivated crimes. Monae also marched in Black Lives Matter protests.

Actor James Cromwell, who became a vegan while shooting the film Babe, began his activism during the civil rights movement and Vietnam War. He was arrested in 1971 for civil disobedience at the famed May Day anti-war protests in Washington D.C.

His half-century-plus of activism has run the gamut from environmental issues, peace efforts, animal rights, and equality.

He has participated in Black Lives Matter protests back to at least 2017, served as a spokesperson for PETA, was arrested during a protest against a dog laboratory in 2019.

Divergent and The Fault in Our Stars actor Shailene Woodley is an avid activist for environmental issues and is active in a number of progressive organizations. While protesting against the Dakota Access Pipeline, Woodley was arrested and charged with criminal trespassing.

Rapper and actor Yasiin Bey, also known as Mos Def, has been outspoken about police brutality and violence against Black Americans.

He held an impromptu concert outside the MTV Video Music Awards in 2006, performing a protest song called Katrina Clap that criticized the Bush administrations response to the Hurricane Katrina disaster. Despite having a permit, Mos Def was arrested for the performance.

French actor Adle Haenel (Portrait of a Lady on Fire) has been active in France's #MeToo movement. Having had her own experiences with abuse and harassment in the film industry, Haenel in 2020 protested Roman Polanski's win at the Csar Awards by walking out of the ceremony with several others.

The daughter of Honduran immigrants, actor America Ferrera has spent most of her career encouraging and mobilizing Latin Americans to be politically active.

Ferrera spoke several times at Democratic national conventions as well as at the 2017 Womens March.

She has also served as a prominent voice in the Keep Families Together movement against family separations at the U.S.-Mexico border and served as an artist ambassador for the global organization Save the Children.

When winning multiple awards for his lead role in the film Joker, Joaquin Phoenix used the awards stage to promote diversity in the film industry and awareness of animal cruelty.

His 2020 speech at the Oscars specifically condemned the dairy industry for its treatment of cows. Phoenix was arrested in 2020 while protesting the climate crisis along with Jane Fonda and Martin Sheen.

Model Emily Ratajkowski has used her platform to advocate for feminism, sexual expression, and a positive body image.

She has designed dresses with partial proceeds supporting Planned Parenthood, and leveraged her Instagram profile to speak out against an Alabama state law that banned abortion.

Upon the nomination and eventual confirmation of Brett Kavanaugh to the Supreme Court, Ratajkowski and others were arrested at a protest in Washington D.C.

Star of Cheers and The Good Place, Ted Danson has been an outspoken voice for environmental issues, particularly those concerning the worlds oceans.

Danson, in late 2019, participated in one of Fondas many protests demanding action on climate change and arrested alongside her.

Along with being legendary performers on stage and screen, married couple Ossie Davis and Ruby Dee were also both prominent activists in the civil rights movement.

Organizing a number of marches, the two were also friends with Martin Luther King Jr., Jesse Jackson, and Malcolm X, with Davis delivering eulogies for King and Malcolm X.

During a period in which politicians such as Joseph McCarthy were leading a fight against communism in America, several individuals and figures in the film industry were targeted and blacklisted for their suspected political alignments. Classic Hollywood actor Humphrey Bogart organized the Committee for the First Amendment and protested the House Un-American Activities Committee.

The multi-talented Sammy Davis Jr. was also politically active, supporting the election campaigns of John F. Kennedy and Robert Kennedy, although he later became close with Richard Nixon a friendship he eventually regretted.

Regardless, Davis remained active in the civil rights movement, especially after the assassination of Martin Luther King Jr., and criticized Nixon for his shortcomings on civil rights.

Australian actor Cate Blanchett has been outspoken up about the role of women in the film industry. Blanchett is also a longtime ambassador for the Australian Conservation Foundation. She has also advocated for the rights and protection of refugees.

Since his time as a student, Lethal Weapon star Danny Glover has been an activist fighting for civil rights and worker unions.

Politically, Glover has endorsed progressive candidates running for president of the United States.

Glover was arrested in 2010 in Maryland during a protest for better working wages and conditions outside French food corporation Sodexo.

In May of 2021, Glover spoke at a rally against anti-Asian bias in New York City.

Hermione Granger herself, actor Emma Watson, was appointed as a U.N. Women Goodwill Ambassador in 2014.

Watson has used her worldwide fame to speak out about womens issues and human rights and declared her support for transgender people after transphobic comments from Harry Potter author J.K. Rowling.

In 2021, Watson was one of 400 signatories in a letter demanding the UK government include women in decision-making roles at the 2021 UN Climate Change Conference.

Read some of Emma Watsons top book recommendations

Martin Sheen may be famous for his acting, but he has stated that activism is what [he does] to stay alive. A humanitarian and social activist, Sheen has been arrested more than 65 times for protesting. Sheen primarily participates in anti-war, pro-worker, and environmental protests.

Continued here:
50 Celebrity Activists With a History of Protesting Injustice - Good Good Good

2023-03-22 | NDAQ:MRKR | Press Release | Marker Therapeutics Inc. – Stockhouse

2022 CLINICAL AND REGULATORY HIGHLIGHTS

2022 CORPORATE AND FINANCIAL HIGHLIGHTS

HOUSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported fiscal year 2022 financial results and provided updates for its clinical development programs.

2022 was a critical year for Marker Therapeutics as we advanced the company on several fronts, including key enhancements to our multiTAA clinical development pipeline and strategic initiatives, including with Wilson Wolf, to leverage our differentiated manufacturing capabilities to generate alternative sources of funding for our clinical programs,” said Peter L. Hoang, President and Chief Executive Officer at Marker Therapeutics. We believe these initiatives will unlock multiple value building opportunities for Marker throughout 2023. We continue to advance our MT-401 Phase 2 ARTEMIS clinical trial and are encouraged by recent data involving measurable residual disease (MRD) positive patients, which suggest MT-401 produced with our new T cell manufacturing process could be well suited for this underserved subset of patients with AML. We anticipate reporting a more expansive data readout from the MRD positive group in the second half of 2023."

Mr. Hoang continued: We also made considerable progress with our MT-601 program, securing FDA clearance for INDs in non-Hodgkin lymphoma and pancreatic cancer. We have initiated enrollment for the lymphoma Phase 1 clinical study of MT-601 and expect to report topline data in early 2024 and expect to initiate enrollment for the pancreatic study by the fourth quarter of 2023. We continue to be energized by the manufacturing services agreement with Wilson Wolf and believe we are on track to earn the additional $1 million bonus provided for in the agreement. Additionally, we see the potential to build on the success of this project with additional revenue-generating opportunities whereby we leverage our unique expertise in technical operations to provide the company with non-dilutive capital to fund our clinical programs.”

MT-401 PHASE 2 ARTEMIS (AML)

New manufacturing process for MT-401:

Adjuvant Patients:

Marker continues to see promising data with MRD+ patients:

Measurable residual disease is an important biomarker in hematological malignancies, such as AML, that is used for prognostic, predictive and monitoring assessments. This term refers to a small number of malignant cancer cells remaining in a patient's body after completion of therapy, despite the absence of clinical and radiological evidence of disease. MRD detection relies on highly sensitive laboratory techniques, such as next-generation sequencing, polymerase chain reaction (PCR), or flow cytometry. The assessment is crucial in AML management as it can provide prognostic information and guide therapeutic decisions, such as the need for additional treatment or close surveillance. Importantly, MRD is a transitional phase prior to development of frank relapse and considered a negative prognostic factor. Thus, the achievement of MRD negativity, defined as the absence of detectable malignant cells, is a favorable prognostic factor and an important treatment goal in AML.

The standard first-line treatment for the last decade had been combination chemotherapy using cytarabine and an anthracycline. However, approximately half of the patients eventually relapse. Eligible patients subsequently proceed to hematopoietic stem cell transplantation (HSCT), but disease relapse after transplant is frequent and remains a major cause of death. To date, there is no approved therapy for post-transplant MRD+ patients, highlighting the need for novel therapies. Therefore, the positive clinical responses observed in MRD+ patients treated with MT-401 may provide a more effective approach to treatment.

Our ARTEMIS trial showed promising clinical responses in post-transplant MRD positive patients highlighting the potential benefit of our multiTAA-specific T cell therapy in patients where no treatments have been approved,” said Dr. Juan F. Vera, Chief Scientific Officer and Chief Operating Officer of Marker Therapeutics. We will continue to track the patients’ disease status and look forward to investigating MT-401 in a larger patient population.”

Dr. Vera continued: Our improved T cell manufacturing process used for multiTAA-specific T cells enables a 9-day ex vivo T cell production, providing a fast turnaround for patient treatment to reach MRD positive patients before relapse.”

Frank Relapse Patients:

MT-601 (Lymphoma)

MT-601 (Pancreatic):

FISCAL YEAR 2022 FINANCIAL RESULTS

Cash Position and Guidance: At December 31, 2022, Marker had cash and cash equivalents of $11.8 million. The Company believes that its existing cash, cash equivalents and restricted cash will fund its operating expenses and capital expenditure requirements into the third quarter of 2023.

R&D Expenses: Research and development expenses were $26.1 million for the year ended December 31, 2022, compared to $27.8 million for the year ended December 31, 2021.

G&A Expenses: General and administrative expenses were $12.8 million for the year ended December 31, 2022, compared to $12.9 million for the year ended December 31, 2021.

Net Loss: Marker reported a net loss of $29.9 million for the year ended December 31, 2022, compared to a net loss of $41.9 million for the year ended December 31, 2021.

About Marker's Phase 2 ARTEMIS Trial

The multicenter Phase 2 AML study is evaluating the clinical efficacy of MT-401 in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting. In the adjuvant setting, approximately 150 patients will be randomized 1:1 to either MT-401 at 90 days post-transplant versus standard-of-care observation, while approximately 40 patients with active disease will receive MT-401 as part of the single-arm group.

The primary objectives of the trial are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients. Additional objectives include, for the adjuvant group, overall survival and graft-versus-host disease relapse-free survival while additional objectives for the active disease group include overall response rate, duration of response, progression-free survival, and overall survival.

About Marker Therapeutics, Inc. Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Forward-Looking Statements

This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401 and our planned trials of MT-401-OTS and MT-601; our ability to use our manufacturing facilities to support clinical and commercial demand; the success of our new manufacturing process and our collaboration with Wilson Wolf Manufacturing Corporation; and our future operating expenses and capital expenditure requirements. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://WWW.SEC.GOV. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contacts

Investors

Tiberend Strategic Advisors, Inc. Daniel Kontoh-Boateng (862) 213-1398 dboateng@tiberend.com

Media

Tiberend Strategic Advisors, Inc. Jason Rando/Casey McDonald (917)-930-6346/ (646) 577-8520 jrando@tiberend.com/cmcdonald@tiberend.com

See original here:
2023-03-22 | NDAQ:MRKR | Press Release | Marker Therapeutics Inc. - Stockhouse

Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan

NEW YORK and LEAMINGTON, Ontario, March 16, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, announced today that Tilray Brands’ stockholders formally approved an amendment to the Company’s Certificate of Incorporation (the “Charter Amendment”). The Charter Amendment will, at the effective time of filing, cancel the Company’s authorized but unissued Class 1 Common Stock and re-allocate such authorized shares to Class 2 Common Stock. At the effective time of filing the Charter Amendment, the Company’s “Class 2 Common Stock” will be reclassified and designated as “Common Stock”. The Charter Amendment is described in more detail in the Company’s Proxy Statement dated September 22, 2022, as supplemented on February 21, 2023.

Excerpt from:
Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan

Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results

Company Announces Intention to Explore Strategic AlternativesSigns Term Sheet with Key Customer to Materially Expand Commercial RelationshipExpands Development Pipeline from 24 to 25 Active Projects as of Fiscal Second Quarter-endSubsequently Transitioned Three Projects to Commercialization with FDA Approval in Fiscal Third Quarter, Expanding Commercial Products from 26 to 29 with 14 CustomersFiscal Second Quarter Earnings Call Scheduled for March 17th, 2023 at 8:30 am Eastern Time

Read this article:
Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results

Novan Announces Closing of $6.0 Million Registered Direct Offering

DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company’s previously announced registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share (or pre-funded warrant) and associated Common Warrant. The Common Warrants will become exercisable six months from the date of issuance at an exercise price of $1.20 per share and will expire five years following the initial exercise date.

Original post:
Novan Announces Closing of $6.0 Million Registered Direct Offering

Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET

Original post:
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

Lifecore Biomedical Announces Intent to Explore Strategic Alternatives

CHASKA, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the Board of Directors of the Company (the “Board”) intends to initiate a process to evaluate the Company’s potential strategic alternatives to maximize value for stockholders. As part of the process, the Board intends to consider a full range of strategic alternatives, which could include a sale of the Company, potential debt or equity financing transactions, or other possible strategic transactions.

View post:
Lifecore Biomedical Announces Intent to Explore Strategic Alternatives

Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship

Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation

See the article here:
Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship

Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp

Significant value unlocked for Enzo shareholders with continued focus on remaining businesses.

See original here:
Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp